Skip to main content

Inflammatory Disease

4
Pipeline Programs
7
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
AMG 357Phase 11 trial
Active Trials
NCT01695876Completed58Est. Oct 2014
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
Lanraplenib.Phase 11 trial
Active Trials
NCT02959138Completed36Est. Oct 2018
Galmed Pharmaceuticals
Galmed PharmaceuticalsIsrael - Tel Aviv
1 program
1
amilo-5MERPhase 1
Quotient Therapeutics
Quotient TherapeuticsMA - Cambridge
1 program
1
amilo-5MERPhase 11 trial
Active Trials
NCT05857215Completed55Est. Jul 2021
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
Lanraplenib.PHASE_1
Lanraplenib.PHASE_1
Holoclara
HoloclaraCA - Los Angeles
1 program
HC002 SADPHASE_11 trial
Active Trials
NCT06670274Completed56Est. May 2025
Celltrion
CelltrionKorea - Incheon
1 program
Infliximab subcutaneousPHASE_31 trial
Active Trials
NCT06059989Recruiting158Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CelltrionInfliximab subcutaneous
HoloclaraHC002 SAD
Quotient Therapeuticsamilo-5MER
Kite PharmaLanraplenib.
AmgenAMG 357

Clinical Trials (5)

Total enrollment: 363 patients across 5 trials

NCT06059989CelltrionInfliximab subcutaneous

InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease

Start: Nov 2021Est. completion: Dec 2025158 patients
Phase 3Recruiting
NCT06670274HoloclaraHC002 SAD

A Dose Escalating Study of HC002 in Healthy Adult Volunteers

Start: Nov 2024Est. completion: May 202556 patients
Phase 1Completed
NCT05857215Quotient Therapeuticsamilo-5MER

A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects

Start: Mar 2021Est. completion: Jul 202155 patients
Phase 1Completed
NCT02959138Kite PharmaLanraplenib.

Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function

Start: Nov 2016Est. completion: Oct 201836 patients
Phase 1Completed
NCT01695876AmgenAMG 357

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects

Start: Oct 2012Est. completion: Oct 201458 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 363 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.